As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...